RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
Hematologic Malignancies
DRUG: RD13-01 cell infusion
Dose-limiting toxicity (DLT), 4 weeks after infusion
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.